Properties (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:Company
|
| gptkbp:acquisition |
gptkb:Ranbaxy_Laboratories
2014 |
| gptkbp:CEO |
gptkb:Sunao_Manabe
|
| gptkbp:clinicalTrials |
Ongoing
|
| gptkbp:employeeCount |
Approximately 10,000
|
| gptkbp:founded |
1897
|
| gptkbp:founder |
gptkb:Kōsuke_Matsumoto
|
| gptkbp:globalPresence |
Yes
|
| gptkbp:headquarters |
gptkb:Tokyo,_Japan
gptkb:Minato,_Tokyo |
| https://www.w3.org/2000/01/rdf-schema#label |
Daiichi Pharmaceutical
|
| gptkbp:industry |
Pharmaceuticals
|
| gptkbp:market |
$20 billion (2021)
|
| gptkbp:parentCompany |
gptkb:Daiichi_Sankyo
|
| gptkbp:partnerships |
Various global pharmaceutical companies
|
| gptkbp:products |
Vaccines
Prescription drugs Over-the-counter medications |
| gptkbp:research_areas |
Cardiology
Central nervous system Gastroenterology Genetic disorders Immunology Oncology Pain management Respiratory diseases Transplantation Urology Women's health Diabetes Ophthalmology Infectious diseases Neurological disorders Pediatrics Rheumatology Endocrinology Hematology Vaccination Dermatology Geriatrics Infectious disease prevention Metabolic disorders Psychiatric disorders Chronic diseases Preventive medicine Health maintenance Men's health Rare diseases Lifestyle diseases Acute diseases Cardiometabolic_disorders Orphan_diseases |
| gptkbp:researchFocus |
Oncology
Diabetes Cardiovascular diseases Infectious diseases |
| gptkbp:revenue |
$4.5 billion (2020)
|
| gptkbp:stockExchange |
gptkb:Tokyo_Stock_Exchange
|
| gptkbp:subsidiary |
gptkb:Daiichi_Sankyo,_Inc.
|
| gptkbp:website |
www.daiichipharm.com
|